Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
Fiche publication
Date publication
avril 2018
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF
Lien Pubmed
Résumé
Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free remission in patients with inflammatory bowel disease. To provide a state-of-the-art overview of thiopurine treatment in inflammatory bowel disease, this clinical review critically summarises the available literature, as assessed by several experts in the field of thiopurine treatment and research in inflammatory bowel disease.
Mots clés
Azathioprine, pharmacology, Drug Therapy, Combination, Gastrointestinal Agents, therapeutic use, Humans, Immunosuppressive Agents, pharmacology, Inflammatory Bowel Diseases, drug therapy, Infliximab, therapeutic use, Mercaptopurine, pharmacology, Neoplasms, epidemiology, Risk Factors, Thioguanine, pharmacology
Référence
J Crohns Colitis. 2018 Apr 27;12(5):610-620